Marginal Zone Lymphoma Education
Marginal zone lymphoma treatment is evolving with BTK inhibitors, lenalidomide combinations, and bispecific antibodies expanding beyond traditional chemoimmunotherapy. Knowledge Med sessions help physicians navigate subtype-specific treatment decisions through interactive case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing marginal zone lymphoma face evolving treatment decisions that interactive, independently reviewed education can help address.
- Differentiating treatment approaches across MZL subtypes (splenic, nodal, extranodal/MALT)
- Selecting systemic therapy: rituximab monotherapy vs combination approaches
- Integrating zanubrutinib and other BTK inhibitors in relapsed disease
- Managing H. pylori-driven gastric MALT lymphoma and other infection-associated subtypes
What Sessions Cover
Knowledge Med MZL sessions use interactive case simulations to address these topics and more.
- Subtype-specific management of marginal zone lymphoma
- First-line treatment selection: when and what to treat
- BTK inhibitors and lenalidomide-rituximab in relapsed MZL
- Emerging agents: bispecific antibodies and PI3K inhibitor alternatives
Interactive MZL Sessions
Case Simulations
Work through realistic marginal zone lymphoma patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key MZL clinical takeaways.
More Hematologic Malignancy Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Chronic Lymphocytic Leukemia
CLL / SLL — First-line therapy selection in CLL: BTK inhibitors vs venetoclax combinations
Diffuse Large B-Cell Lymphoma
DLBCL — Frontline DLBCL: pola-R-CHP and risk-adapted strategies
Multiple Myeloma
Frontline induction: triplet vs quadruplet therapy and transplant decisions
Acute Myeloid Leukemia
AML — Molecular-guided frontline therapy selection in AML
Join a MZL Session
Third-party, non-promotional marginal zone lymphoma education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session